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SECOND to chronic allograft dysfunction, membranousnephropathy (MN) is the most frequent cause of ne-
phrotic syndrome in renal transplantation.1 This pathology can
be caused by recurrence of the primary renal disease, the
development of de novo glomerulopathy, or by a transplanted
glomerular disease (present but unrecognized in the donor).2
De novo MN was first described more than 25 years ago 3 and
is the most common de novo disease after engraftment. It has
an incidence of 2 to 9% in most series, with the highest rates
being reported by centres who perform routine graft biop-
sies,2,4 De novo disease tends to present later than the
recurrent forms, and typically occurs 2 years post transplanta-
tion, although cases have been described at 4 months.2
CASE REPORT
Emergency haemodialysis was started on an 18-year-old
female Caucasian (HLA A 22, 28; B 8, 18; DR 3, 5) who
presented with severe uremia. There was no past history of
disease, namely she denied edema, frothy urine, hyperten-
sion, or other urinary symptoms. Biopsy was not performed
due to small regular kidneys.
Aged 21, she received a cadaveric renal allograft from a
CMV IgG-positive donor. The CMV status of the patient
was unavailable at this stage. The back-table donor biopsy
showed a normal kidney with mild interstitial edema and
occasional atrophic tubules. Immunosuppression was
started consisting of cyclosporine A, azathioprine, and
prednisone. There was immediate function, with serum
creatinine of 1.8 mg/dL on the second day, which dropped
to 1.3 mg/dL at discharge on day 15.
One month posttransplant, a rise in serum creatinine to
3.9 mg/dl led to a graft biopsy being performed, which
showed a mild acute cellular rejection. Treatment with
methylprednisolone 500 mg  3 was attended by return to
previous creatinine value of 1.4 mg/dL. At this time, CMV
immediate early antigen (IEA) became positive. She was
treated with anti-CMV hyperimmune globulin and gancy-
clovir. Despite this, CMV antigenemia (positive IEA) was
present until month 5. At this time, a positive dipstick for
protein led to a 24-hour collection being performed, which
showed 3.6 g of proteinuria to be present. Although serum
creatinine remained stable at 1.0 mg/dL, a second biopsy
was performed and showed MN of the graft. Immunoper-
oxidase staining with monoclonal serum for CMV was
negative. After review of the 1 month, biopsy with adequate
staining, it was thought that thickening of the basal mem-
branes was already present, alongside acute rejection.
At month 8 serum creatinine was 0.8 mg/dL, proteinuria
was absent, and the patient edema free. The most frequent
causes of secondary MN have been excluded (drug-induced,
tumor-associated, autoimmune, infection-related).
Four weeks after the first positive IEA result, the patient
was CMV IgM negative and IgG positive. Ten weeks later
she became IgM positive and IgG positive. These findings
were present after 12 more weeks.
COMMENTS
MN of the graft was found 1 month posttransplantation.
Although histological examination of the patient’s native
kidneys was not possible, gender, age, and absence of a
history of nephrotic syndrome or hypertension make pri-
mary membranous nephropathy very unlikely as the pri-
mary renal disease. We therefore assume de novo disease to
be present in the graft. The persistence (3.5 months) of
CMV antigenemia makes a causal relationship likely, de-
spite the immunoperoxidase findings.
The patient’s B18 and DR3 haplotypes have been associ-
ated with a very high risk for the occurrence of primary MN.5
In fact, there may be a relative risk of 12 for developing MN
if DR3 is inherited.6 We suggest that the risk conferred may
apply to development of de novo disease in a renal graft.
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